Related Experiment Video

Updated: Oct 15, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

Comparative Cardiovascular Safety of Novel Hormonal Agents in Metastatic Castration-Resistant Prostate Cancer Using

Jason Hu1, Armen G Aprikian2, Marie Vanhuyse3

  • 1Division of Urology, Department of Surgery, McGill University, Montreal, Canada.

Clinical Genitourinary Cancer
|October 28, 2021
PubMed
Abstract

Insights

Abiraterone acetate (ABI) may increase cardiovascular hospitalization risk compared to enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC) patients. Specifically, ABI users showed a higher incidence of heart failure hospitalizations in real-world data.

Area of Science:

  • Oncology
  • Cardiology
  • Pharmacology

Background:

  • Novel hormonal agents (NHAs) like abiraterone acetate (ABI) and enzalutamide (ENZ) are standard treatments for metastatic castration-resistant prostate cancer (mCRPC).
  • While generally well-tolerated, clinical trials have indicated potential cardiovascular (CV) toxicity signals for these agents.
  • Real-world data on the comparative CV safety of ABI and ENZ in mCRPC patients is limited.

Purpose of the Study:

  • To compare the cardiovascular safety of abiraterone acetate (ABI) versus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC).
  • To assess the incidence of cardiovascular-related hospitalizations in real-world clinical practice for patients treated with ABI or ENZ.

Main Methods:

  • A retrospective cohort study utilized Quebec public healthcare administrative databases.
  • First-time users of NHAs (ABI or ENZ) between 2011 and 2016 were identified.
  • Inverse probability of treatment weighting (IPTW) was applied to adjust for baseline characteristics, including pre-existing cardiovascular disease, to analyze cardiovascular-related hospitalizations.

Main Results:

  • The study included 2,183 mCRPC patients (1,773 on ABI, 410 on ENZ).
  • Crude incidence rates of CV-related hospitalization were 9.8 events/100 person-years for ABI and 7.1 events/100 person-years for ENZ.
  • Abiraterone acetate users had a significantly higher risk of CV-related hospitalization (IPTW-HR 1.82) and specifically heart failure hospitalization (IPTW-HR 2.88) compared to enzalutamide users.

Conclusions:

  • Real-world data suggests abiraterone acetate (ABI) may be associated with a greater risk of cardiovascular-related hospitalization than enzalutamide (ENZ) in mCRPC patients.
  • The increased risk appears particularly pronounced for heart failure hospitalizations.
  • These findings offer valuable insights for clinicians managing cardiovascular risks in mCRPC patients undergoing NHA treatment, warranting further investigation.
Keywords:
AbirateroneAdverse EventsCardiotoxicityEnzalutamideReal-World Evidence

More Related Videos

Serum and Plasma Copy Number Detection Using Real-time PCR09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.6K
Pre-clinical Orthotopic Murine Model of Human Prostate Cancer07:01

Pre-clinical Orthotopic Murine Model of Human Prostate Cancer

Published on: August 29, 2016

14.6K

Related Concept Videos

Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
293
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
343